| Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma D Ennishi, A Jiang, M Boyle, B Collinge, BM Grande, S Ben-Neriah, ... Journal of Clinical Oncology 37 (3), 190, 2019 | 325 | 2019 |
| Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma BM Grande, DS Gerhard, A Jiang, NB Griner, JS Abramson, TB Alexander, ... Blood, The Journal of the American Society of Hematology 133 (12), 1313-1324, 2019 | 209 | 2019 |
| Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma SE Arthur, A Jiang, BM Grande, M Alcaide, R Cojocaru, CK Rushton, ... Nature communications 9 (1), 1-14, 2018 | 143 | 2018 |
| Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma A Mottok, SS Hung, EA Chavez, B Woolcock, A Telenius, LC Chong, ... Blood, The Journal of the American Society of Hematology 134 (10), 802-813, 2019 | 119 | 2019 |
| The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH LK Hilton, J Tang, S Ben-Neriah, M Alcaide, A Jiang, BM Grande, ... Blood, The Journal of the American Society of Hematology 134 (18), 1528-1532, 2019 | 98 | 2019 |
| Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma CK Rushton, SE Arthur, M Alcaide, M Cheung, A Jiang, KM Coyle, ... Blood advances 4 (13), 2886-2898, 2020 | 71 | 2020 |
| TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma D Ennishi, S Healy, A Bashashati, S Saberi, C Hother, A Mottok, FC Chan, ... Nature medicine 26 (4), 577-588, 2020 | 66 | 2020 |
| Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing P Pararajalingam, KM Coyle, SE Arthur, N Thomas, M Alcaide, ... Blood, The Journal of the American Society of Hematology 136 (5), 572-584, 2020 | 56 | 2020 |
| Characterization of DLBCL with a PMBL gene expression signature G Duns, E Viganò, D Ennishi, C Sarkozy, SS Hung, E Chavez, K Takata, ... Blood, The Journal of the American Society of Hematology 138 (2), 136-148, 2021 | 27 | 2021 |
| Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors V Shanmugam, JW Craig, LK Hilton, MH Nguyen, CK Rushton, ... Blood Advances 5 (1), 71-83, 2021 | 19 | 2021 |
| Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms KC Yang, SE Kalloger, JJ Aird, MKC Lee, C Rushton, KL Mungall, ... Cell reports 37 (2), 2021 | 17 | 2021 |
| Characterization of the genetic landscape of high‐grade B‐cell lymphoma, NOS–an LLMPP project BJ Collinge, LK Hilton, J Wong, S Ben‐Neriah, CK Rushton, GW Slack, ... Hematological Oncology 39, 2021 | 16 | 2021 |
| Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns K Dreval, LK Hilton, M Cruz, H Shaalan, S Ben-Neriah, M Boyle, ... Blood 142 (6), 561-573, 2023 | 15 | 2023 |
| Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment M Nowicka, LK Hilton, M Ashton-Key, CE Hargreaves, C Lee, R Foxall, ... Blood advances 5 (15), 2945-2957, 2021 | 9 | 2021 |
| Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma LK Hilton, HS Ngu, B Collinge, K Dreval, S Ben-Neriah, CK Rushton, ... Journal of Clinical Oncology 41 (25), 4164-4177, 2023 | 7 | 2023 |
| Ultrasensitive detection of circulating tumor DNA in lymphoma via targeted hybridization capture and deep sequencing of barcoded libraries M Alcaide, C Rushton, RD Morin Lymphoma: Methods and Protocols, 383-435, 2019 | 7 | 2019 |
| PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers A Jiang, LK Hilton, J Tang, CK Rushton, BM Grande, DW Scott, RD Morin Blood cancer discovery 1 (3), 244-257, 2020 | 4 | 2020 |
| IDENTIFYING MUTATIONS ENRICHED IN RELAPSED‐REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE C Rushton, M Alcaide, M Cheung, N Thomas, S Arthur, N Michaud, ... Hematological Oncology 37, 35-36, 2019 | 3 | 2019 |
| Concerning data inconsistencies in Burkitt lymphoma genome study CK Rushton, K Dreval, RD Morin Blood 142 (10), 933-936, 2023 | 2 | 2023 |
| whole genome sequencing of matched primary and relapsed DLBCL reveals distinct evolutionary dynamics associated with relapse timing LK Hilton, B Collinge, CK Rushton, S Ben‐Neriah, K Dreval, BM Grande, ... Hematological Oncology 39, 2021 | 2 | 2021 |
